News Releases
-
Jul 2, 2019
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement...
-
Jun 26, 2019
Insmed Incorporated (Nasdaq: INSM) today announced the closing on June 25, 2019 of the issuance of an additional 1,442,307 shares of common stock pursuant to the full exercise of the underwriter's...
-
Jun 6, 2019
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and...
-
Jun 4, 2019
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement...
-
May 24, 2019
Insmed Incorporated (Nasdaq: INSM) today announced the closing of the previously announced public offering of its common stock. Insmed issued and sold in the public offering 9,615,385 shares of...
-
May 21, 2019
Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 9,615,385 shares of its common stock, at a price to the public of $26.00 per share...
-
May 20, 2019
Insmed Incorporated (Nasdaq: INSM) announced today that it has commenced an underwritten public offering of up to $250 million of its common stock. In addition, Insmed intends to grant the...
-
May 20, 2019--ARIKAYCE Plus Guideline-Based Therapy (GBT) Associated with Significantly Higher Rates of Sustained Culture Conversion on Therapy and Durable Culture Conversion Three Months Post-Treatment Compared with GBT Alone--
Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today presented new data from the ongoing...
-
May 7, 2019-- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 --
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the...
-
Apr 30, 2019
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first...
